When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ALBO - Albireo advancing mid-stage study of IBAT inhibitor in NASH/NAFLD
Albireo Pharma Inc.
Albireo Pharma (ALBO-0.9%) completes the enrollment of 47 subjects in a Phase 2 clinical trial evaluating ileal bile acid transporter (IBAT) elobixibat (5 mg) in patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH), the first such study assessing an IBAT inhibitor in these patients according to the company.
More news on: Albireo Pharma, Inc., Healthcare stocks news,